Pentraxin-3 levels are associated with vasculitis and disease activity in childhood-onset systemic lupus erythematosus

Objectives Childhood-onset systemic lupus erythematosus (cSLE) is a multisystemic autoimmune disease characterized by inflammatory organ damage by means of vasculitis. Pentraxin-3 (PTX3) is expressed locally at the sites of inflammatory processes, predominantly from endothelial cells. In adult studi...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2017-09, Vol.26 (10), p.1089-1094
Main Authors: Sahin, S, Adrovic, A, Barut, K, Durmus, S, Gelisgen, R, Uzun, H, Kasapcopur, O
Format: Article
Language:English
Subjects:
Adolescent
Age Factors
Age of Onset
Antibodies
Autoantibodies
C-Reactive Protein - metabolism
Cardiolipin
Case-Control Studies
Child
Children
Deoxyribonucleic acid
DNA
Endothelial cells
Female
Humans
Laboratories
Lupus
Lupus Erythematosus, Systemic - blood
Lupus Erythematosus, Systemic - physiopathology
Male
Pentraxins
Procalcitonin
Raynaud Disease - etiology
Rheumatology
Serum Amyloid P-Component - metabolism
Serum levels
Severity of Illness Index
Systemic lupus erythematosus
Vasculitis
Vasculitis - blood
Vasculitis - etiology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives Childhood-onset systemic lupus erythematosus (cSLE) is a multisystemic autoimmune disease characterized by inflammatory organ damage by means of vasculitis. Pentraxin-3 (PTX3) is expressed locally at the sites of inflammatory processes, predominantly from endothelial cells. In adult studies, PTX3 has shown to be an indicator of active vasculitis both in large-vessel and small-vessel vasculitides, as well as in SLE. Moreover, in SLE it has found to be correlated with disease activity, and with some of the clinical manifestations and laboratory parameters. We aimed to ascertain if PTX3 might be a significant mediator in cSLE and if it might indicate active vasculitis during the course of the disease. Methods Serum PTX3 levels were measured in 76 patients with cSLE and 41 healthy subjects. We have investigated its relation with disease activity, damage, clinical features, laboratory parameters and medications. Results Serum levels of PTX3 were found to be increased in cSLE compared to healthy controls (mean ± SD; 10.6 ± 8.2 ng/mL vs 2.7 ± 1.3 ng/mL, p 
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203317699286